Skip to main content
Smaller Larger Print

MENU

Here you can find our current FISH probes

Download PDF document

  • Diagnostic AML panel (RUNX1T1::RUNX1 t(8;21)(q22;q22), BCR::ABL1 t(9;22)(q34;q11.2), PML::RARA t(15;17)(q24.1;q21.1), CBFß::MYH11 inv(16)(p13q22)/t(16;16)(p13;q22))
  • Prognostic AML panel (RPN1::MECOM t(3;3)(q21.3;q26.2)/inv(3)(q21.3q26.2), EGR1/RPS14 deletion 5q/monosomy 5, DEK::NUP214 t(6;9)(p22;q34), KMT2E/D7S522/MET deletion 7q/monosomy 7, KMT2A(MLL)::MLLT3(AF9) t(9;11)(p21.3;q23.3), KMT2A(MLL) t(11q23), TP53/ATM deletion 17p13/i(17q))
  • BCR::ABL1 t(9;22)(q34;q11.2)
  • CBFβ::MYH11 inv(16)(p13q22)/t(16;16)(p13;q22)
  • D20S108 (20q12), RH7808 (20q13.3), D8Z2 (deletion 20q, trisomy 8)
  • DEK::NUP214 t(6;9)(p22;q34)
  • EGR1 (5q31), RPS14 (5q33) with control in 5p15 (deletion 5q/monosomy 5)
  • KMT2A(MLL) t(11q23)
  • KMT2A(MLL)::MLLT1(ENL) t(11;19)(q23.3;p13.3)
  • KMT2A(MLL)::MLLT3(AF9) t(9;11)(p21.3;q23.3)
  • KMT2A(MLL)::AFDN(MLLT4) t(6;11)(q27;q23.3)
  • KMT2E (7q22), D7S522/MET (7q31.2) with control D7Z1 (deletion 7q/monosomy 7)
  • PML::RARA t(15;17)(q24.1;q21.1)
  • RPN1::MECOM t(3;3)(q21.3;q26.2)/inv(3)(q21.3q26.2)
  • RUNX1T1::RUNX1 t(8;21)(q22;q22)
  • TP53 (17p13) in combination with ATM (11q22) (deletion 17p13/11q22)

  • BCR::ABL1 t(9;22)(q34;q11.2)
  • TP53 (17p13.1) in combination with ATM (11q22.3) (deletion 17p/i(17q))

Because chromosome analysis is the standard procedure to provide important diagnostic and prognostic information for MDS, we perform FISH analysis only if chromosome analysis  is not sufficient.

  • Complete MDS panel (RPN1::MECOM t(3;3)(q21.3;q26.2)/inv(3)(q26.2), EGR1/RPS14 deletion 5q/monosomy 5, KMT2E/D7S522/MET deletion 7q/monosomy 7, D20S108/D8Z2 deletion 20q/trisomy 8, TP53/ATM deletion 17p13/i(17q))
  • D20S108 (20q12), RH7808 (20q13.3), D8Z2 (deletion 20q, trisomy 8)
  • EGR1 (5q31), RPS14 (5q33) with control in 5p15 (deletion 5q/monosomy 5)
  • KMT2E (7q22), D7S486 (7q31) with control D7Z1 (deletion 7q/monosomy 7)
  • RPN1::MECOM t(3;3)(q21.3;q26.2)/inv(3)(q21.3q26.2), TP53 (17p13) in combination with ATM (11q22) (deletion 17p/i(17q), deletion 11q)
  • TP53 (17p13) in combination with ATM (11q22) (deletion 17p13/i(17q), deletion 11q22)

  • BCR::ABL1 t(9;22)(q34;q11.2)
  • ETV6::RUNX1 (deletion 12p/ETV6-rearrangement)
  • D20S108 (20q12), RH74808 (20q13.3), D8Z2 (deletion 20q/trisomy 8)
  • FGFR1 t(8p11)
  • JAK2 t(9p24)
  • KMT2E (7q22), D7S522/MET (7q31.2) with control D7Z1 (deletion 7q/monosomy 7)
  • PCM1::JAK2 t(8;9)(p22;q24)
  • PDGFRA/CHIC2/FIP1L1 (deletion 4q12, FIP1L1-::PDGFR-rearrangement)
  • PDGFRB t(5q32)
  • TP53 (17p13) in combination with ATM (11q22) (deletion 17p13/i(17q), deletion 11q22)

  •  Complete B-CLL/SLL panel (D6S1594/MYB deletion 6q, ATM/TP53 deletion 11q22/deletion 17p13, D12Z3/DLEU1/LAMP1 trisomy 12/deletion 13q14/deletion 13q, IGH-rearrangement t(14q32))
  • ATM (11q22) and TP53 (17p13) (deletion 11q22, deletion 17p13)
  • BCL3 t(19q13)
  • CCND1::IGH t(11;14)(q13;q32))
  • Centromere 12 (D12Z3), DLEU1 (13q14), LAMP1 (13q34) (trisomy 12, deletion 13q14, deletion 13q)
  • IGH t(14q32)
  • IGH::BCL2 t(14;18)(q32;q21)/trisomy 18
  • MYB (6q23) with controls in 6q21 (D6S1594) and D6Z1 (deletion 6q)

  • Complete NHL panel (D6S1594/MYB deletion 6q, ATM/TP53 deletion 11q22/deletion 17p13, D12Z3/DLEU1/LAMP1 trisomy 12/deletion 13q14/deletion 13q, IGH-rearrangement t(14q32))
  • ALK t(2p23) in ALK+ DLBCL
  • ATM (11q22) and TP53 (17p13) (deletion 11q22, deletion 17p13)
  • BCL3 t(19q13)
  • BCL6 t(3q27)/gain 3q
  • CCND1::IGH t(11;14)(q13;q32)
  • CCND3::IGH t(6;14)(p21;q32)
  • Centromere 12, DLEU1 (13q14), LAMP1 (13q34) (trisomy 12, deletion 13q14, deletion 13q)
  • IGH t(14q32)
  • IGH::BCL2 t(14;18)(q32;q21)/gain 18q
  • MALT1 t(18q21)
  • MYB (6q23) with controls in 6q21 (D6S1594) and D6Z1 (deletion 6q)
  • MYC t(8q24)/gain 8q24
  • MYC::IGH t(8;14)(q24;q32)

  • ATM (11q22) and TP53 (17p13) (deletion 11q22, deletion 17p13)
  • ETV6::RUNX1 (deletion 12p)
  • MYC t(8q24)/gain 8q24
  • TCRα/δ t(14q11)

For FISH analysis, “magnetic activated cell sorting” (MACS) will be initially performed to isolate CD138+ plasma cells.

Cave: In the diagnostic process for plasma cell diseases, FISH analysis is recommended as the gold standard, so a chromosome analysis will not be performed.

  • Complete plasma cell neoplasia panel (CDKN2C/CKS1B deletion 1p32.3/amplification 1q21, ATM/TP53 deletion/gain 11q22/deletion 17p13, FGFR3::IGH t(4;14)(p16;q32), IGH::MAF t(14;16)(q32;q23), IGH::MAFB t(14;20)(q32;q12))
  • ATM (11q22) and TP53 (17p13) (deletion/gain 11q22, deletion 17p13)
  • CDKN2C (1p32.2), CKS1B (1q21) (deletion 1p32.3/amplification 1q21)
  • FGFR3::IGH t(4;14)(p16;q32)
  • IGH::MAF t(14;16)(q32;q23)
  • IGH::MAFB t(14;20)(q32;q12)
  • MYC t(8q24)
  • MYC::IGH t(8;14)(q24;q32)

  • Aneuploidies of the chromosomes 4 (D4Z1), 10 (D10Z1), 17 (D17Z1)
  • BCR::ABL1 t(9;22)(q34;q11.2)
  • CDKN2A (p16, 9p21) with control CEP9 (deletion 9p)
  • ETV6::RUNX1 t(12;21)(p13;q22)
  • ETV6::RUNX1 (deletion 12p/amplification RUNX1)
  • IGH t(14q32)
  • KMT2A(MLL) t(11q23)
  • KMT2A(MLL)::AFF1(AF4) t(4;11) (q21.3-q22.1;q23.3)
  • KMT2A(MLL)::MLLT1(ENL) t(11;19)(q23.3;p13.3)
  • KMT2A(MLL)::AFDN(MLLT4) t(6;11)(q27;q23.3)
  • MYC t(8q24)
  • MYC::IGH t(8;14)(q24;q32)
  • TCF3::PBX1 t(1;19)(q23;p13.3) with HLF (17q22)

  • BCR::ABL1 t(9;22)(q34;q11.2)
  • CDKN2A (p16, 9p21) with control CEP9 (deletion 9p)
  • KMT2A(MLL) t(11q23)
  • TCRα/δ t(14q11)

  • Centromere 12, DLEU (13q14), LAMP1 (13q34) (trisomy 12, deletion 13q14, deletion 13q)
  • D20S108 (20q12), RH7808 (20q13.3), D8Z2 (deletion 20q, trisomy 8)
  • EGR1 (5q31), RPS14 (5q33) with control in 5p15 (deletion 5q/monosomy 5)
  • KMT2E (7q22), D7S522/MET (7q31.2) with control D7Z1 (deletion 7q/monosomy 7)

  • Chromosome X- and Y-specific probes (DXZ1, DYZ3)